Insmed Inc (INSM)

Add to Watchlists

Create an Alert

25.84 +0.00 +0.00% NASDAQ May 23, 16:59 Delayed 2m USD

Insmed Inc News

Wire

Headline

Time (ET)
Yahoo

What Did Insmed Incorporated's (NASDAQ:INSM) CEO Take Home Last Year?

05/22 10:53
Yahoo

The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

05/22 07:34
SA Breaking News

Insmed prices stock offering at $26

05/22 06:52
MT Newswires

Insmed Prices More Than 9.6 Mln Shares at $26 Each in Underwritten Public Offering

05/21 22:49
PR Newswire

Insmed Announces Pricing of Public Offering of Common Stock

05/21 20:56
Yahoo

The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

05/21 07:40
MT Newswires

MT Newswires After-Hours News Movers

05/20 17:48
SA Breaking News

Insmed's Arikayce shows sustained benefit in late-stage lung disease study

05/20 16:30
MT Newswires

Insmed Presents New Phase 3 Data for ARIKAYCE, Launches $250 Mln Public Offering of Shares

05/20 16:28
PR Newswire

Insmed Announces Proposed Public Offering of Common Stock

05/20 16:05
PR Newswire

New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

05/20 16:01
SA Breaking News

Key events next week - healthcare

05/10 07:49
Yahoo

Insmed (INSM) Q1 2019 Earnings Call Transcript

05/07 23:24
Yahoo

Edited Transcript of INSM earnings conference call or presentation 7-May-19 12:30pm GMT

05/07 15:28
MT Newswires

Insmed Reports Better-Than-Expected Q1 Results, Shares Decline as Net Loss Widens

05/07 15:01
Yahoo

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

05/07 08:55
Yahoo

See what the IHS Markit Score report has to say about Insmed Inc.

05/07 08:03
Yahoo

Insmed: 1Q Earnings Snapshot

05/07 07:52
PR Newswire

Insmed Reports First Quarter 2019 Financial Results and Provides Business Update

05/07 07:30
MT Newswires

--Analyst Actions: Credit Suisse Lifts Outperform-Rated Insmed's PT to $40 From $36 on Strong Clinical Demand for Arikayce

05/03 10:34

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial

{{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.